You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Glatiramer Acetate

Showing 1 - 25 of 1,134
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in

Completed
  • Multiple Sclerosis
    • Aurora, Colorado
      University of Colorado Hospital
    Mar 4, 2022

    Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

    Completed
    • Multiple Sclerosis
    • interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
    • Prague, Czechia
      IMPULS Endowment Fund
    Mar 7, 2023

    Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

    Recruiting
    • Multiple Sclerosis
    • Diroximel Fumarate
    • +8 more
    • Eden Prairie, Minnesota
      OptumInsight
    Jan 9, 2023

    Acute Decompensated Heart Failure, Cytokine Storm, Inflammatory Response Trial in Jerusalem (Copaxone, guideline directed

    Completed
    • Acute Decompensated Heart Failure
    • +3 more
    • Copaxone
    • guideline directed medical therapy (GDMT)
    • Jerusalem, Israel
      Hadassah Ein Kerem medical center-hospital ,Cardiology Departmen
    Aug 15, 2023

    Cinnomer® in Multiple Sclerosis Treatment in Iran

    Completed
    • Relapsing Multiple Sclerosis
    • Glatiramer Acetate
    • (no location specified)
    Jun 13, 2021

    Relapsing Multiple Sclerosis (RMS) Trial in United States (Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate)

    Recruiting
    • Relapsing Multiple Sclerosis (RMS)
    • Phoenix, Arizona
    • +3 more
    Jul 20, 2022

    Multiple Sclerosis Trial in Buffalo (Copaxone)

    Completed
    Has Results
    • Multiple Sclerosis
    • Buffalo, New York
      Jacobs Neurological Institute
    Feb 25, 2021

    Relapsing-remitting Multiple Sclerosis Trial (BCD-063, Copaxone-Teva, Placebo)

    Completed
    • Relapsing-remitting Multiple Sclerosis
    • (no location specified)
    Sep 8, 2021

    Relapsing Multiple Sclerosis Trial (Placebo, BIIB061, Interferon-beta1)

    Not yet recruiting
    • Relapsing Multiple Sclerosis
    • Placebo
    • +3 more
    • (no location specified)
    Mar 22, 2021

    Copaxone Subcutaneous Injection Syringe Special Drug Use-Result

    Recruiting
    • Multiple Sclerosis
    • Glatiramer acetate
    • Tokyo, Japan
      Takeda selected site
    Jan 12, 2022

    Relapsing-remitting Multiple Sclerosis Trial in Stockholm (Rituximab)

    Active, not recruiting
    • Relapsing-remitting Multiple Sclerosis
    • Stockholm, Sweden
      Fredrik Piehl
    Apr 8, 2022

    s in Patients With Relapsing Multiple Sclerosis

    Recruiting
    • Relapsing Multiple Sclerosis
    • ofatumumab
    • +2 more
    • Untermeiting, Bayern, Germany
    • +35 more
    Aug 12, 2022

    Primary Progressive Multiple Sclerosis Trial in Israel, Moldova, Republic of (GA Depot 40mg once monthly, GA Depot 25mg once

    Recruiting
    • Primary Progressive Multiple Sclerosis
    • GA Depot 40mg once monthly
    • GA Depot 25mg once monthly
    • Haifa, Israel
    • +6 more
    Oct 30, 2022

    Multiple Sclerosis Trial in Ashkelon, Haifa, Tel Aviv (GA Depot 80 mg, GA Depot 40 mg)

    Active, not recruiting
    • Multiple Sclerosis
    • GA Depot 80 mg
    • GA Depot 40 mg
    • Ashkelon, Israel
    • +2 more
    Aug 9, 2021

    Multiple Sclerosis Trial in Newark (Betaseron, Copaxone)

    Completed
    Has Results
    • Multiple Sclerosis
    • Newark, New Jersey
      New Jersey Medical School
    Oct 18, 2021

    Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,

    Recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • Early Highly Effective Therapies Group
    • Escalation Therapies Group
    • Aurora, Colorado
    • +30 more
    Jul 22, 2022

    Multiple Sclerosis Trial in Worldwide (Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon)

    Active, not recruiting
    Has Results
    • Multiple Sclerosis
    • Alemtuzumab GZ402673
    • +11 more
    • Wien, Austria
    • +20 more
    Jun 16, 2022

    Long-Term Safety of Vumerity and Tecfidera in Multiple Sclerosis

    Not yet recruiting
    • Multiple Sclerosis
    • Diroximel Fumarate
    • +2 more
    • (no location specified)
    Mar 2, 2023

    Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Trial in Amsterdam (DMT)

    Recruiting
    • Multiple Sclerosis
    • +2 more
    • Amsterdam, Netherlands
      Amsterdam UMC
    Oct 13, 2020

    Multiple Sclerosis Trial in Worldwide (Ofatumumab, First line DMT)

    Recruiting
    • Multiple Sclerosis
    • Bayonne, Bayonne Cedex, France
    • +42 more
    Jul 25, 2022

    Multiple Sclerosis (MS) Registries

    Active, not recruiting
    • Progressive Multifocal Leukoencephalopathy
    • Tysabri
    • Cambridge, Massachusetts
      Research Site
    Mar 21, 2022

    Relapsing-Remitting Multiple Sclerosis Trial in United States (Glatiramer acetate)

    Completed
    Has Results
    • Relapsing-Remitting Multiple Sclerosis
    • Glatiramer acetate
    • Los Angeles, California
    • +10 more
    Feb 14, 2020

    Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Glatiramer acetate (GA), Placebo)

    Completed
    Has Results
    • Relapsing Remitting Multiple Sclerosis
    • Glatiramer acetate (GA)
    • Placebo
    • Birmingham, Alabama
    • +175 more
    Dec 7, 2021

    Multiple Sclerosis Trial in Genova (7-day Fasting-Mimicking Diet (7-DAY FMD))

    Active, not recruiting
    • Multiple Sclerosis
    • 7-day Fasting-Mimicking Diet (7-DAY FMD)
    • Genova, Italy
      Ospedale San Martino
    Sep 8, 2023

    Multiple Sclerosis Trial in Worldwide (Copaxone®)

    Completed
    Has Results
    • Multiple Sclerosis
    • Cullman, Alabama
    • +96 more
    Dec 7, 2021